Steve Schonfeld’s Apogee Therapeutics APGE Stock Holding History

Steve Schonfeld’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.12M	Buy	31,059 +7,971	+35%	+$718K	0.01%	724
2026 Q1	$1.94M	Sell	23,088 -6,057	-21%	-$440K	0.01%	829
2025 Q4	$2.2M	Buy	+29,145	New	+$1.84M	0.01%	842
2025 Q1	–	Sell	-70,766	Closed	-$3.21M	–	2192
2024 Q4	$3.21M	Buy	+70,766	New	+$3.61M	0.02%	650

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Steve Schonfeld's APGE Position: Q2 2026 in Review

Steve Schonfeld increased its Apogee Therapeutics (APGE) stake by 35% in Q2 2026, buying an estimated $718K and bringing the position to 31,059 shares worth $4.12M. The position accounts for 0.01% of the portfolio, ranked #724.

Steve Schonfeld first reported a position in APGE in Q4 2024 and has held it in 4 quarters since. 285 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Steve Schonfeld held 31,059 shares of Apogee Therapeutics worth $4.12M as of Q2 2026.
Steve Schonfeld bought 7,971 Apogee Therapeutics shares in Q2 2026, an estimated $718K.
Apogee Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #724 holding.
Steve Schonfeld first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 4 quarters since.
285 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.